9 results about "GABAA receptor" patented technology

This invention relates to a cinnabar-2-oxide compound, its preparation method, and its uses. The cinnabar-2-oxide compound is shown in formula (I). By oxidizing a nitrogen atom to an N-oxide and then combining it with a heteroaryl group, the above-mentioned cinnabar-2-oxide compound achieves good α2-GABAA receptor affinity and positive regulatory activity. Simultaneously, it has the potential to significantly reduce PXR (pregnane X receptor) activation, thereby reducing drug-drug interactions and improving drug efficacy or safety.

This invention relates to a crystal form, preparation method, and application of a GABAA receptor modulator. Specifically, it provides the crystal form, preparation method, and application of the compound of formula (I) in the preparation of a GABAA receptor modulator drug.

Disclosed herein are GABA receptor antagonists for the treatment of epileptic conditions. A Receptor Modulators and GABA A Also disclosed herein are compositions comprising the GABA receptor modulators described herein. A A method of treating an epileptic condition in a subject by administering a receptor modulator or composition.

The invention provides a steroid compound containing a 3-methyl allopregnenolone mother nucleus structure as well as a preparation method, a pharmaceutical composition and application of the steroid compound, and belongs to the technical field of medicines. The invention provides a steroid compound containing a 3-methyl pregnenolone mother nucleus structure, and pharmaceutically acceptable salts, stereoisomers, tautomers, prodrugs, solvates or isotope compounds of the steroid compound. The steroid compound containing the 3-methyl pregnenolone mother nucleus structure has a structure as shown in a formula I. The invention further provides a preparation method of the steroid compound containing the 3-methyl pregnenolone mother nucleus structure. The steroid compound containing the 3-methyl allopregnenolone mother nucleus structure has a strong positive regulation effect on a GABAA receptor, and has potential application to treatment of central nervous system related diseases.

Described herein are salts (e.g., fumarate salts) of 3-(2,5-difluorophenyl)-7-[1,1-di(methyl-d 3 )ethyl-2,2,2-d 3 ]-6-[(1-methyl-1H-1,2,4-triazol-5-yl)methoxy]-1,2,4-triazolo[4,3-b]pyridazine and particles comprising 3-(2,5-difluorophenyl)-7-[1,1-di(methyl-d 3 )ethyl-2,2,2-d 3 ]-6-[(1-methyl-1H-1,2,4-triazol-5-yl)methoxy]-1,2,4-triazolo[4,3-b]pyridazine or a salt thereof, and uses thereof.

The invention provides methods and related compositions for preventing neurocognitive decline associated with chronic stress, age, and neurodegenerative diseases. The methods described here are based upon the use of alpha5-GABAA receptor agonists to slow or prevent deleterious morphological changes in dendrites of the hippocampus and prefrontal cortex, which eventually manifest in functional decline and the neurocognitive deficits.

Provided in the present invention are a fused ring compound, and an intermediate thereof and the use thereof. Specifically, the present invention relates to a compound as shown in general formula (I), a cis-trans isomer thereof, an enantiomer thereof, a diastereomer thereof, a racemate thereof, a solvate thereof, a hydrate thereof, or a pharmaceutically acceptable salt thereof, or a prodrug thereof. The compound of the present invention has a good modulatory effect on an α5-GABAA receptor, and has good pharmaceutical application prospects.

The present disclosure concerns the novel compounds 3α-ethyl-3β-hydroxy-5α-androstan-17-one and 3α-ethyl-3β-hydroxy-5α-androstan-17-one, the medical use thereof and in particular use in the treatment of diseases and disorders associated with an α3 subtype of the GABAA receptor, for example 5 treatment of obesity, hyperphagia disorder, Prader-Willi's syndrome, polycystic ovarian syndrome, and / or diabetes. Said disclosure is also concerned with reducing and / or preventing overweight. Additionally, related pharmaceutical and cosmetic compositions are disclosed as well as treatment against alcoholism and substance abuse.

Disclosed are compositions and methods for treating benzodiazepine misuse and / or use disorder. A method of treating benzodiazepine misuse and / or use disorder includes administering to a subject in need thereof of an effective amount of a compound that provides both partial modulator and antagonist effects at GABAA receptors.